Cargando…
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling
BACKGROUND: Metabolic reprogramming is a common feature in cancer, and it is critical to facilitate cancer cell growth. Isocitrate Dehydrogenase 1/2 (IDH1 and IDH2) mutations (IDHmut) are the most common genetic alteration in glioma grade II and III and secondary glioblastoma and these mutations inc...
Autores principales: | Yamashita, Alex Shimura, da Costa Rosa, Marina, Stumpo, Vittorio, Rais, Rana, Slusher, Barbara S, Riggins, Gregory J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920530/ https://www.ncbi.nlm.nih.gov/pubmed/33681764 http://dx.doi.org/10.1093/noajnl/vdaa149 |
Ejemplares similares
-
Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma()()
por: Hanaford, Allison R., et al.
Publicado: (2019) -
Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice
por: Bell, Benjamin J., et al.
Publicado: (2022) -
Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects
por: Krečmerová, Marcela, et al.
Publicado: (2022) -
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010) -
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)